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Abdominal adiposity depots are correlates of
adverse cardiometabolic risk factors in Caucasian
and African-American adults
RL Newton Jr, C Bouchard, G Bray, F Greenway, WD Johnson, E Ravussin, D Ryan
and PT Katzmarzyk
Pennington Biomedical Research Center, LSU System, Baton Rouge, LA, USA
Objective: Accumulation of adipose tissue is associated with cardiometabolic risks. Although visceral adipose tissue (VAT) has
been strongly implicated in this relationship, there is still some debate regarding the contribution of abdominal subcutaneous
adipose tissue (SAT). The purpose of this study was to determine the contribution of abdominal SAT to cardiometabolic risk
factors, independent of total and visceral adiposity. These relationships were assessed in Caucasian and African Americans.
Design: It is a cross-sectional analysis of the Pennington Center Longitudinal Study.
Subjects: Data were extracted from 1246 participants. Total body fat mass (FM) was measured by dual-energy X-ray absorptio-
metry, whereas abdominal VAT and SAT areas (cm
2) were measured with computed tomography. The cardiometabolic risk
factors included resting blood pressure (BP), fasting blood glucose and triglyceride concentrations and high-density lipoprotein
cholesterol (HDL-C).
Results: Positive relationships across tertiles of VAT were seen for the participants with high glucose, high BP and low HDL-C
(Po0.043). There was also a significant increase in the percentage of participants with two or more cardiometabolic risk factors
across most tertiles of abdominal SAT (Po0.042). Logistic regression analysis showed that in univariate models, all adiposity
measures were significantly associated with increased odds of having all risk factors in men and women. In multivariate models,
VAT was significantly associated with most risk factors across gender. Abdominal SAT and FM (odds ratios (ORs) 1.3–2.1; all
Po0.05) were associated with fewer risk factors after accounting for VAT. VAT (OR¼5.9 and 5.3) and SAT (OR¼2.0 and 1.8)
were both associated with higher odds of the presence of two or more cardiometabolic risk factors in both males and females
(Po0.001).
Conclusion: The data suggest that abdominal SAT is not protective against unfavorable cardiometabolic risk profiles. These
conclusions were consistent across ethnic groups.
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Introduction
Abdominal obesity is the hallmark of central or android
obesity, and has been suggested as a key component of the
metabolic syndrome.
1 Abdominal fat includes the visceral
adipose tissue (VAT) fraction, which has been consistently
associated with cardiometabolic risk factors, including
diabetes,
2,3 dyslipidemia,
4,5 atherosclerosis,
6 decreased
insulin sensitivity
4,5,7,8 and the metabolic syndrome.
9,10
The relationship between VAT and cardiometabolic risk
factors is believed to be because of the fact that VAT produces
endocrine, lipolytic and inflammatory factors
6,11,12 that
are known to be associated with insulin resistance and
heart disease. It has also been shown that VAT is correlated
with ectopic fat deposition in skeletal muscle and liver,
a phenomenon that is known to substantially increase the
risk of metabolic abnormalities.
13 These findings have been
shown across different age, gender and ethnic groups.
Abdominal subcutaneous adipose tissue (SAT) has also
been shown to be positively associated with increased cardio-
metabolic risk.
6,10,12 The associations with SAT tend to be
weaker than associations between VAT and cardiometabolic
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6,10 However, there have been some inconsistent
findings regarding the contribution of SAT to the risk of
metabolic syndrome and cardiovascular disease.
13 Gluteal fat
has been shown to be protective of cardiometabolic disease.
14
Some studies have shown few or even no relationships
between SAT and the risk factors for cardiometabolic
disease.
3,7 In addition, several epidemiological studies have
shown that SAT was negatively associated with risk factors for
cardiometabolic disease.
5,9,15–17 However, these findings were
evident only in the highest tertile of VAT, were seen in only
one gender group (for example, males) or were seen for only
one risk factor (for example, triglycerides). Such findings are
consistent with the observation that, in susceptible indivi-
duals, excess fat can also be deposited ectopically in the liver,
kidney, pancreas, skeletal muscles, heart and so on,
11 which
leads to a decreased ability of these organs to function
properly, resulting in a poor cardiometabolic profile. SAT in
general, and abdominal SAT in particular, is believed to be the
major storage depot for excess fat, preventing ectopic fat
deposition. Therefore, one could speculate that a large
abdominal SAT for a given level of total adiposity and VAT
may be metabolically advantageous and protective.
Given the current uncertainities regarding the contribution
of SAT to cardiometabolic risk, the purpose of this study was to
assess the relationship between abdominal SAT and cardio-
metabolic risk factors. Previous studies have conducted similar
analyses, but have not controlled for both total and visceral
adiposity, confounding the findings. Therefore, we will control
for these effects. We also used computed tomography (CT)
data to estimate cross-sectional areas of abdominal fat. In
addition, our sample is ethnically diverse, which allows for the
relationship between adiposity and cardiometabolic risk
factors to be assessed across ethnic groups.
Materials and methods
Study sample
The Pennington Center Longitudinal Study (PCLS) is
designed to assess the effects of lifestyle factors and obesity
on the development of chronic disorders such as type 2
diabetes, cardiovascular disease and cancer. The sample is
composed of participants who have enrolled in clinical
studies at the Pennington Biomedical Research Center
(PBRC) since 1992. The current investigation is limited to
cross-sectional analyses of individuals who participated in
studies requiring a CT scan of the L4–L5 abdominal region,
a full-body dual-energy X-ray absorptiometry (DXA) scan,
resting blood pressure (BP) and fasting blood draws in
which glucose, triglycerides and cholesterol levels were
assayed (since 1998). These measurements represented the
first observation and, therefore, were obtained before any
intervention. There were 1246 adults who met these criteria.
Each volunteer provided written informed consent, and all
the Pennington Center Longitudinal Study procedures were
approved by the Pennington Biomedical Research Center
institutional review board.
Measures
Body composition. Body mass index: Standing height was
measured to the nearest 0.1cm by a wall-mounted stadi-
ometer (Holtain Ltd, Dyfed, UK). Standard procedures were
followed in which the participants removed their shoes,
traction was placed on their head in order to align it with
the Frankfort Plane and the slide was lowered until it reached
the vertex of the skull while the volunteer inhaled. Weight
was measured to the nearest 0.1kg using a digital scale
after heavy outer clothing and pocket items were removed.
Two measurements of height and weight were taken. A third
measurement was taken if the first two measurements were
not within 0.5cm or 0.5kg of each other. Body mass index
was calculated as the weight in kilograms divided by the
height in meters squared (kgm
 2).
CT: Abdominal VAT and SAT areas (cm
2) were measured
with one of three different CT scanners: GE High
Speed Advantage (1998–2000; n¼498), GE LightSpeed Plus
(2001–2006; n¼697), and GE LightSpeed VCT (2007–2008;
n¼51, all from GE Healthcare, Princeton, NJ, USA).
Participants lay in a supine position with arms overhead to
obtain a cross-sectional image at the L4–L5 intervertebral
space. The procedures for defining VAT and SAT have been
described by Smith et al.
5 CT scanners were calibrated daily
to air. CT imaging was analyzed with commercially available
software (Analyze Direct, Rochester, MN, USA).
DXA: Total body fat mass (FM; kg) was measured using
a whole-body DXA scanner. FM was calculated as percentage
body fat (%fat) scale weight, where %fat was derived from
DXA and the scale weight was the weight measured from a
digital scale. One of two Hologic models, QDR 2000 and
QDR 4500 (Hologic, Bedford, MA, USA), was used for
imaging. The QDR 2000 (n¼537) was used until 2006. The
QDR 4500 (n¼709) was used along with the QDR 2000 from
2001 to 2006, and then used exclusively thereafter.
A subsample of participants (n¼32) had DXA scans con-
ducted by both machines in order to assess comparability.
The agreement for %fat between the machines was high
(R
2¼0.987), and an equation was developed to convert the
QDR 2000 data to be comparable with QDR 4500 data
(Y¼0.8015Xþ2.3903). Phantoms were used for calibration
and documentation of the stability of measures over time.
Each participant’s scan was analyzed with the latest software
QDR for Windows V11.2 (Hologic).
Cardiometabolic risk factors. BP: All BP measurements were
taken manually using a stethoscope and standard sphygmo-
manometer, or in some cases using a validated Omron
automatic measuring device (Omron, Bannockburn, IL,
USA). Resting BP measurements were obtained after a
5-min rest, with the participant in a semi-recumbent
position in a quiet room. Each measurement was taken
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measurement, and the average of the two measurements was
recorded. Participants were not allowed to engage in
vigorous exercise, ingest food or caffeine or smoke within
30min of measurement. Upper-arm length and circumfer-
ences of the right arm were measured in order to
establish the appropriate cuff size. The Korotkoff sounds
were used to establish the first-and fifth phases,
and all measurements were recorded in mmHg. High BP
was defined as systolic BP X130mmHg or diastolic BP
X85mmHg or self-reported hypertension (13 individuals).
Blood glucose and lipids: Blood was collected following a
12-h fast. Glucose and lipids were analyzed on a Beckman
Coulter DXC600 (Beckman Coulter, Brea, CA, USA). High
glucose was defined as fasting plasma glucose X100mgdl
 1
or self-reported treatment with a hypoglycemic agent or
insulin. High triglycerides were defined as X150mgdl
 1.
Low high-density lipoprotein cholesterol (HDL-C) was
defined as p40mgdl
 1 for males or p50mgdl
 1 for females.
Covariates. Age, smoking, menopausal status and ethnicity
served as covariates. Age was computed from birth and
observation dates. Self-reported smoking status was deter-
mined from questionnaire responses during initial telephone
screening, and the participants were categorized as non-
smokers, current smokers or former smokers. Participants
were classified as ‘Yes’ or ‘No’ to being a ‘current smoker’ for
the statistical analyses. Menopausal status (premenopausal/
postmenopausal) was determined in females on the basis
of their age and responses to questions regarding their
reproductive history. Females aged X55 years or those who
indicated that they can no longer have children because of
reaching menopause were considered to be postmenopausal.
Participants self-classified themselves as African American
or Caucasian.
Statistical analysis
The associations between adiposity and cardiometabolic risk
factors (low HDL-C, high BP, high glucose, high triglycerides)
were assessed in two ways. In one set of analyses, risk factor
values across tertiles of abdominal SAT were assessed within
each tertile of VAT. These means were adjusted for age, body
mass index and FM. It is important to adjust for both VAT
and FM when assessing the independent effect of SAT
because there are strong positive interrelationships between
the variables. In another set of analyses, hierarchical multi-
ple logistic regression analyses were used to assess the
relationships between adiposity variables and cardiometa-
bolic risk factors. The presence or absence of high BP (systolic
BP X130mmHg or diastolic BP X85mmHg), high triglycer-
ides (X150mgdl
 1), low HDL-C (p40mgdl
 1 for males and
p50mgdl
 1 for females), high low-density lipoprotein
(fasting glucose X100mgdl
 1) and the presence or absence
of two or more cardiometabolic risk factors were modeled as
dependent variables. Demographic and adiposity variables
served as independent variables. The adiposity measures,
SAT, VAT and FM, were modeled as continuous variables.
Six models were investigated. Model 1 included the demo-
graphic variables age, smoking status, ethnicity and meno-
pausal status. VAT was added to the demographic variables in
Model 2 and abdominal SAT was added to the demographic
variables in Model 3. In Model 4, both VAT and SAT were
entered into the regression analysis along with the demo-
graphic variables. Model 5 included the demographic
variables and FM and Model 6 included the demographic
variables and both FM and VAT.
Correlations were run to determine the association among
the adiposity variables. We assessed multicollinearity, which
is a measure of how much a given variable is explained by
the other independent variables, to determine whether
certain independent variables should be excluded from
appearing together in the logistic regression models. We
considered multicollinarity to be present if tolerance was
o0.10.
18 SAS version 9.0 (Cary, NC, USA) was used for all
statistical analyses. The level of significance was set at 0.05.
Results
A summary of the characteristics of the sample is presented
in Table 1. Approximately 40% of the sample were male and
33% were African Americans. The average age was 44.5 years.
The overall mean for VAT was 118cm
2, 374cm
2 for SAT and
28kg of FM.
Age, ethnicity and FM-adjusted means (Table 2), and the
percentage of participants (Table 3) with each risk factor, are
reported by tertiles of SAT within tertiles of VAT. The only
risk factor to decrease significantly across levels of SAT was
high BP. This occurred in females within the lowest VAT
tertile (P¼0.043). Otherwise, the percentages of males with
high BP (P¼0.031) and females with low HDL-C (P¼0.028)
increased across levels of SAT in the middle and highest VAT
tertiles, respectively. In addition, the percentage of males
and females having two or more cardiometabolic risk factors
increased significantly across tertiles of SAT in each VAT
tertile (Po0.042), except for men in the highest VAT tertile
(P¼0.058).
SAT and FM were highly correlated (r¼0.93; Po0.001).
The correlations between VAT and SAT (r¼0.36) and
between VAT and FM (r¼0.53) were also significant.
Tolerance values for SAT and FM were o0.083 in males,
and were 0.14 and 0.11 in females, respectively. Although
the values in females do not reach the threshold for
tolerance (o0.10), greater than 85% of the variance in SAT
and FM is explained by the other independent variables.
Therefore, SAT and FM were not included together in the
logistic regression models for either gender group.
Table 4 displays the odds ratios (ORs) for the relationship
between the adiposity measures and the cardiometabolic
risk factors. In Model 1, which included only demographic
variables, age was significantly associated with increased
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both males and females (Po0.001). In Model 2, VAT was
added to the model with the demographic variables and was
significantly associated with increased odds of having each
individual risk factor in men (OR¼1.4–2.6; Po0.05) and
women (OR¼1.8–2.9; Po0.001). VAT was also significantly
associated with increased odds of having two or more risk
factors across both genders (males: OR¼10.1; 95% con-
fidence interval (CI), 6.5–15.7; females: OR¼8.1; 95% CI,
5.8–11.4). SAT was significantly associated with increased
odds of having each individual risk factor in men (OR¼
1.4–1.8; Po0.05) and women (OR¼1.5–1.7; Po0.001) in
Model 3, in which it was added to the demographic
variables. SAT was also associated with increased odds of
Table 1 Anthropometric, clinical and biochemical characteristics (means (s.d.)) of the sample stratified by gender and ethnicity
Overall Males Females
African American Caucasian African American Caucasian
Mean (s.d.)
N 1246 100 406 311 429
Age (years) 44.5 (13.1) 36.5 (13.8)
a 44.4 (13.5) 40.2 (11.6)
a 49.6 (11.5)
BMI (kgm
 2) 29.7 (5.1) 29.3 (5.2) 30.0 (4.6) 30.6 (5.4)
a 29.0 (5.1)
SBP (mmHg) 120.5 (13.1) 122.1 (11.1) 121.6 (12.1) 119.0 (13.7) 120.0 (13.9)
DBP (mmHg) 76.6 (8.4) 76.8 (9.1) 78.0 (8.2) 77.2 (8.8)
a 74.9 (7.8)
Glucose (mmoll
 1) 5.6 (1.0) 5.6 (0.9) 5.8 (1.2) 5.5 (0.9) 5.5 (0.8)
Triglycerides (mmoll
 1) 1.5 (0.9) 1.2 (0.8)
a 1.8 (1.1) 1.0 (0.6)
a 1.5 (0.9)
HDL-C (mmoll
 1) 1.4 (0.4) 1.2 (0.3) 1.2 (0.3) 1.5 (0.4) 1.5 (0.4)
SAT (cm
2) 374.1 (153.6) 283.0 (163.0) 309.1 (136.8) 441.8 (147.9)
a 407.7 (136.0)
VAT (cm
2) 117.8 (64.9) 90.3 (57.9)
a 140.9 (70.8) 91.0 (49.2)
a 121.8 (61.2)
FM (kg) 28.4 (9.7) 21.3 (9.9)
a 25.9 (9.2) 31.3 (9.4) 30.2 (8.9)
%
High glucose
b 39.6 45.0 47.8 34.1 34.5
High BP
c 33.5 38.0 34.5 30.9 33.3
Smoking
d 4.6 12.0
a 2.2 4.8 4.9
Post menopause
e 33.8 FF 11.6
a 49.9
Abbreviations: BP, blood pressure; BMI, body mass index; DBP, diastolic blood pressure; FM, total body fat mass; HDL-C, high-density lipoprotein cholesterol;
SAT, subcutaneous abdominal adipose tissue; SBP, systolic blood pressure; VAT, visceral adipose tissue.
aSignificant at 0.05 between ethnic groups within gender.
bHigh glucoseF‘Yes’ if glucose X100mgdl
 1 (55.5mmoll
 1) or self-reported diabetes.
cHigh BPF‘Yes’ if SBP X130mmHg or DBP X85mmHg or self-reported
hypertension.
dSmokingF‘Yes’ if current smoker or self-reported during phone interview for recruitment.
ePost menopauseF‘Yes’ if female aged 454 years or
reported post menopause.
Table 2 Age, ethnicity and FM-adjusted risk factor means by sex-specific SAT tertiles within sex-specific VAT tertiles
Males Females
SAT tertile 1 SAT tertile 2 SAT tertile 3 P-value SAT tertile 1 SAT tertile 2 SAT tertile 3 P-value
VAT tertile 1 (mean±s.e.m.)
SBP (mmHg) 119.9±2.1 119.9±1.5 116.9±2.3 0.595 116.3±2.0 116.2±1.4 112.5±2.1 0.344
DBP (mmHg) 75.6±1.5 73.7±1.1 73.1±1.7 0.519 74.8±1.4 73.9±0.9 73.2±1.4 0.811
Glucose (mmoll
 1) 5.3; 5.1–5.4 5.4; 5.3–5.5 5.3; 5.1–5.5 0.251 5.0; 4.9–5.1 5.1; 5.0–5.2 5.2; 5.0–5.3 0.400
Triglyceride (mmoll
 1) 0.78; 0.65–0.93 0.94; 0.83–1.06 1.08; 0.89–1.31 0.114 0.75; 0.65–0.87 0.78; 0.71–0.87 0.94; 0.81–1.10 0.127
VAT tertile 2 (mean±s.e.m.)
SBP (mmHg) 119.3±2.3 122.6±±1.8 123.8±2.3 0.384 122.0±1.9 119.0±1.3 119.1±1.9 0.411
DBP (mmHg) 76.4±1.6 79.9±1.2 80.6±1.6 0.123 76.9±1.2 76.6±0.8 76.0±1.2 0.911
Glucose (mmoll
 1) 5.6; 5.3–5.9 5.8; 5.5–6.0 5.9; 5.6–6.2 0.406 5.4; 5.2–5.6 5.5; 5.3–5.6 5.4; 5.2–5.6 0.936
Triglyceride (mmoll
 1) 1.20; 0.99–1.46 1.42; 1.22–1.64 1.49; 1.23–1.80 0.291 1.19; 1.02–1.37 1.20; 1.08–1.33 1.00; 0.86–1.16 0.145
VAT tertile 3 (mean±s.e.m.)
SBP (mmHg) 125.2±2.8 124.0±2.1 128.1±2.7 0.369 126.5±2.1 121.9±1.5 123.1±2.1 0.160
DBP (mmHg) 81.6±1.9 81.6±1.4 81.6±1.8 0.999 78.4±1.2 76.4±0.9 77.5±1.2 0.295
Glucose (mmoll
 1) 6.3; 5.7–6.9 5.8; 5.4–6.2 6.0; 5.5–6.6 0.121 6.1; 5.8–6.4 6.0; 5.7–6.2 5.6; 5.4–5.9 0.160
Triglyceride (mmoll
 1) 1.76; 1.38–2.24 1.81; 1.50–2.17 1.85; 1.46–2.34 0.961 1.36; 1.17–1.57 1.35; 1.21–1.51 1.53; 1.32–1.78 0.418
Abbreviations: DBP, diastolic blood pressure; FM, total body fat mass; SAT, subcutaneous abdominal adipose tissue; SBP, systolic blood pressure; VAT, visceral
adipose tissue.
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Males Females
SAT tertile 1 SAT tertile 2 SAT tertile 3 P-value SAT tertile 1 SAT tertile 2 SAT tertile 3 P-value
VAT tertile 1 (%)
High BP
a 14.0 19.6 21.4 0.581 19.5 19.3 7.4 0.043
High glucose
b 12.3 33.9 33.9 0.008 7.3 12.1 12.4 0.515
High triglycerides
c 5.3 10.7 10.7 0.499 3.7 7.2 8.6 0.449
Low HDL-C
d 10.5 17.9 25.0 0.138 11.0 20.5 22.2 0.122
2+ Risk factors
e 7.0 25.0 30.4 0.003 6.1 15.7 32.1 o0.001
VAT tertile 2 (%)
High BP
a 22.8 33.9 46.4 0.031 30.5 33.7 35.4 0.811
High glucose
b 61.4 53.6 58.9 0.700 34.2 34.9 28.1 0.598
High triglycerides
c 31.6 46.4 39.3 0.288 23.2 28.9 20.7 0.486
Low HDL-C
d 19.3 30.4 30.4 0.290 18.3 28.9 34.2 0.060
2+ Risk factors
e 42.1 67.9 80.4 o0.001 40.2 55.4 70.7 o0.001
VAT tertile 3 (%)
High BP
a 48.2 51.8 58.9 0.556 51.9 42.9 50.0 0.475
High glucose
b 62.5 51.8 57.1 0.539 58.0 64.3 57.3 0.608
High triglycerides
c 66.1 60.7 55.4 0.531 48.2 41.7 45.1 0.715
Low HDL-C
d 30.4 37.5 37.5 0.681 30.9 38.1 51.2 0.028
2+ Risk factors
e 85.7 96.4 96.4 0.058 74.1 84.5 89.0 0.041
Abbreviations: BP, blood pressure; FM, total body fat mass; HDL-C, high-density lipoprotein cholesterol; SAT, subcutaneous abdominal adipose tissue; VAT, visceral
adipose tissue.
aHigh BP defined as SBP X130mmHg and DBP X85mmHg.
bHigh glucose defined as X100mgdl
 1 (5.55mmoll
 1).
cHigh triglycerides defined as
X150mgdl
 1 (1.70mmoll
 1).
dLow HDL-C defined as o40mgdl
 1 (1.04mmoll
 1) for males and o50mgdl
 1 (1.3mmoll
 1) for females.
e2+ Risk factors defined
as two or more of high BP, high glucose, high triglycerides or low HDL-C.
Table 4 Odds ratios (95% CI) of having specific cardiometabolic risk factors per standard deviation of VAT, SAT, or FM
Males Females
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
VAT Model 2 Model 4 Model 6 Model 2 Model 4 Model 6
High triglyceride 2.6 (2.0–3.3)** 2.6 (1.9–3.6)** 2.6 (1.8–3.7)** 2.3 (1.9–2.8)** 2.1 (1.7–2.7)** 2.2 (1.7–2.9)**
Low HDL 1.8 (1.4–2.2)** 1.5 (1.2–2.0)* 1.5 (1.1–2.1)* 2.4 (2.0–3.0)** 2.2 (1.7–2.8)** 2.2 (1.7–2.9)**
Diabetes 1.4 (1.1–1.8)* 1.2 (0.9–1.6) 1.1 (0.8–1.4) 2.9 (2.3–3.7)** 3.0 (2.3–3.9)** 2.9 (2.2–4.0)**
High BP 2.2 (1.7–2.8)** 1.8 (1.3–2.4)** 1.7 (1.2–2.3)* 1.8 (1.5–2.2)** 1.7 (1.4–2.2)** 1.6 (1.2–2.1)*
2+ Risk factors 10.1 (6.5–15.8)** 5.9 (3.7–9.7)** 5.3 (3.1–9.1)** 8.1 (5.8–11.4)** 5.3 (3.6–7.7)** 4.3 (2.9–6.3)**
SAT Model 3 Model 4 Model 3 Model 4
High triglycerides 1.5 (1.2–1.8)** 1.0 (0.8–1.2) F 1.7 (1.4–2.0)** 1.1 (0.9–1.4) F
Low HDL 1.5 (1.2–1.8)** 1.2 (1.0–1.6) F 1.7 (1.4–2.0)** 1.2 (0.9–1.4) F
Diabetes 1.4 (1.2–1.7)* 1.3 (1.0–1.6)* F 1.7 (1.4–2.0)** 1.0 (0.8–1.2) F
High BP 1.8 (1.5–2.2)** 1.4 (1.1–1.8)* F 1.5 (1.2–1.8)** 1.1 (0.9–1.4) F
2+ Risk factors 4.0 (2.9–5.3)** 2.0 (1.4–2.7)** 3.3 (2.7–4.1)** 1.8 (1.4–2.3)** F
FM Model 5 Model 6 Model 5 Model 6
High triglycerides 1.7 (1.4–2.1)** F 1.0 (0.7–1.3) 1.7 (1.4–2.1)** F 1.1 (0.8–1.4)
Low HDL 1.5 (1.3–1.9)** F 1.2 (0.9–1.6) 1.7 (1.5–2.1)** F 1.1 (0.9–1.4)
Diabetes 1.5 (1.2–1.9)** F 1.5 (1.1–1.9)* 1.9 (1.5–2.2)** F 1.0 (0.8–1.3)
High BP 1.9 (1.5–2.3)** F 1.4 (1.0–1.8)* 1.6 (1.3–1.9)** F 1.2 (0.9–1.5)
2+ Risk factors 4.6 (3.4–6.2)** 2.0 (1.4–2.9)** 4.2 (3.3–5.3)** 2.1 (1.6–2.8)**
Abbreviations: BP, blood pressure; CI, confidence interval; FM, total body fat mass; HDL, high-density lipoprotein; OR, odds ratio; SAT, subcutaneous abdominal
adipose tissue; VAT, visceral adipose tissue. Odds ratios of having specific risk factor per standard deviation of VAT, SAT or FM unadjusted for other adiposity variables
in (A) Model 2 (demographic variables + VAT), Model 3 (demographic variables + SAT) and Model 5 (demographic variables + FM), and adjusted for other adiposity
variables in (B) Model 4 (demographic variables + VAT and SAT) and (C) Model 6 (demographic variables + VAT and FM). High triglycerides, triglycerides
X150mgdl
 1; Low HDL, HDL o50mgdl
 1 (women), HDL o40mgdl
 1 (men); Diabetes, glucose X126mgdl
 1 or reported diabetes; High BP, systolic BP
X140mmHg or diastolic BP X90mmHg or reported hypertension. 2+ Risk factors, having two or more of high triglyceride, low HDL, diabetes or high BP. *Po0.05;
**Po0.0001.
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(OR¼4.0; 95% CI, 2.9–5.3) and females (OR¼3.3; 95% CI,
2.7–4.1). When both VAT and SAT were included in the
same model (Model 4), VAT (OR¼1.5–2.6; Po0.05) was
significantly associated with increased odds of having high
triglycerides, low HDL-C and high BP, and SAT (OR¼1.3; 1.4;
Po0.05) was significantly associated with diabetes and high
BP in men. In women, VAT (ORs¼1.7–3.0; Po0.001) was
significantly associated with all risk factors, whereas
SAT was not associated with any risk factor. Both VAT
(males: OR¼6.0; 95% CI, 3.7–9.7; females: OR¼5.3; 95% CI,
3.6–7.6) and SAT (males: OR¼2.0; 95% CI, 1.4–2.7; females:
OR¼1.8; 95% CI, 1.4–2.3) were significantly associated with
having two or more risk factors (Po0.001).
In Model 5, FM was added to the demographic variables
and was significantly associated with all individual risk
factors in men (OR¼1.5–1.9; Po0.001) and women
(OR¼1.6–1.9; Po0.001). FM was also significantly asso-
ciated with the presence of two or more risk factors
(males: OR¼4.7; 95% CI, 3.4–6.4; females: OR¼4.3; 95%
CI, 3.4–5.4; Po0.001). In Model 6, in which both VAT and
FM were assessed simultaneously, VAT was significantly
associated with all risk factors in men (except diabetes;
OR¼1.5–2.6; Po0.05) and women (OR¼1.6–2.9; Po0.05).
FM was significantly associated with diabetes and high BP
in men (OR¼1.4; 1.5; Po0.05), but was not associated
with any risk factor in women. Furthermore, both VAT (males:
OR¼5.2; 95% CI, 3.0–9.1; females: OR¼4.3; 95% CI, 2.9–6.3)
and FM (males: OR¼2.0; 95% CI, 1.4–3.0; females: OR¼2.2;
95% CI, 1.6–2.9) were significantly associated with increased
odds of having two or more risk factors (Po0.001).
In all models, age and ethnicity were significantly asso-
ciated with increased odds of having one or more cardio-
metabolic risk factors (data not shown). Given these
relationships, we conducted the logistic regression analyses
separately for all significant age and ethnicity effects. There
were three significant age by VAT interaction effects: high BP
in men (P¼0.037), high triglycerides in women (P¼0.004)
and low HDL in women (P¼0.036).
Discussion
Our results showed that abdominal SAT is positively
associated with increased odds of having two or more
cardiometabolic risk factors. The findings from two different
analyses lead to this conclusion. The logistic regression
showed that SAT was associated with increased odds favoring
the presence of two or more cardiometabolic risk factors.
Specifically, every standard deviation increase of SAT was
associated with double the odds of having two or more
cardiometabolic risk factors. The tertile analysis descriptively
showed that the percentage of individuals having two or
more cardiometabolic risk factors increased across SAT
and VAT tertiles. These effects were shown in both males
and females.
There was little evidence in this study that abdominal SAT
was associated with a reduced cardiometabolic risk profile,
which has been proposed by others.
5,9,15–17 Of the four risk
factors assessed, only the percentage of females with high BP
decreased significantly across levels of SAT, and this finding
was only shown within the lowest VAT tertile. The logistic
regression analyses showed that SAT was associated with
increased odds of having each individual risk factor in
univariate analyses and increased risk of having two or more
risk factors whether or nor VAT was accounted for. Other
studies assessing the relationship between abdominal
SAT and cardiometabolic risk factors have also shown few
protective effects of abdominal SAT. Porter et al.
17 showed
increased odds of meeting criteria for the metabolic
syndrome across the middle and highest tertiles of SAT.
In addition, a reduced cardiometabolic risk profile across
levels of SAT has been demonstrated only at the highest
VAT tertiles,
17,19 only in males
17,19 or has only been shown
with select outcomes such as lower triglycerides.
17,20 Beyond
these specific findings, the vast majority of results in
previous studies showed either a non-significant or a positive
association between abdominal SATand cardiometabolic risk
factors. Therefore, our results are strongly supportive of
the view that abdominal SAT worsens the cardiometabolic
risk profile.
One goal of the study was to assess the effect of ethnicity
on the odds of having one or more cardiometabolic risk
factors. The initial set of regression analyses showed that
ethnicity was significantly associated with increased odds
of having one or more metabolic risk factors in males and
females. These associations were not surprising because
African Americans have a higher prevalence of hypertension,
diabetes and low-density lipoprotein and lower levels of
triglycerides. However, the vast majority of subsequent
regression analyses, including the interaction terms for
ethnicity, showed few significant effects. These findings
show that the observed relationships do not differ signi-
ficantly by ethnicity.
Our study has several strengths. There were a large number
of African-American participants in the cohort, which
allowed us to take ethnicity into account when conducting
the analyses. In addition, our study employed imaging
techniques to assess adiposity. Finally, our tertile analysis
adjusted for FM, which has seldom been reported.
17 Con-
trolling for FM is important to understand the independent
effect of SAT, as FM increased across tertiles of SAT within
tertiles of VAT (data not shown).
The study was mainly limited by the non-randomly
selected sample. The participants in the cohort were
volunteers for studies conducted at the Pennington Bio-
medical Research Center and their characteristics are un-
likely to be representative of those of the Louisiana or US
population, which limits the generalization of our findings.
There was some within-instrument variation across the study
time period. For example, there were two different DXA
scanners, three CT scanners and two different BP monitoring
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all measurement instruments were calibrated against one
another. Additionally, although state-of-the-art imaging
measurements were conducted, we did not have a quanti-
fication of the deep and the superficial layers of SAT or
assessments for upper trunk and limb adiposity. It has been
shown that distinct sub-compartments of abdominal SAT
relate differently to disease risk,
5,8,21 which is an area for
further research. Several studies have shown that peripheral
SAT is protective of cardiovascular disease risk.
7,9,22 The
effect for peripheral SAT could very well be different form
that of abdominal SAT,
23 as indicated by the results of this
study.
Our study showed that abdominal SAT is adversely
associated with cardiometabolic risk factors. Overall, there
were unfavorable relationships between abdominal SAT
and cardiometabolic risk factors in both males and females,
and across both ethnic groups. Higher levels of abdominal
SAT was associated with increased odds of having two or
more cardiometabolic risk factors. Furthermore, Caucasian
females had increased odds with each standard deviation
increase in VAT for given levels of FM or abdominal VAT. In
sum, this investigation indicates that larger quantities of
abdominal SAT contribute to an adverse cardiometabolic
profile.
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